Related references
Note: Only part of the references are listed.C1-esterase inhibitor concentrate rescues erythrocytes from complement-mediated destruction in autoimmune hemolytic anemia
Diana Wouters et al.
BLOOD (2013)
Eculizumab: A Review of Its Use in Atypical Haemolytic Uraemic Syndrome
Gillian M. Keating
DRUGS (2013)
Complement in Immune and Inflammatory Disorders: Pathophysiological Mechanisms
Daniel Ricklin et al.
JOURNAL OF IMMUNOLOGY (2013)
Complement in Immune and Inflammatory Disorders: Therapeutic Interventions
Daniel Ricklin et al.
JOURNAL OF IMMUNOLOGY (2013)
Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic-Uremic Syndrome
C. M. Legendre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Diagnosis and treatment of cold agglutinin mediated autoimmune hemolytic anemia
Sigbjorn Berentsen et al.
BLOOD REVIEWS (2012)
C1 esterase inhibitor concentrate in 1085 Hereditary Angioedema attacks - final results of the IMPACT2 study
T. J. Craig et al.
ALLERGY (2011)
How I manage cold agglutinin disease
Sigbjorn Berentsen
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Achievements and Limitations of Complement Inhibition by Eculizumab in Paroxysmal Nocturnal Hemoglobinuria: The Role of Complement Component 3
A. M. Risitano et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2011)
Classification and therapeutic approaches in autoimmune hemolytic anemia: an update
Marc Michel
EXPERT REVIEW OF HEMATOLOGY (2011)
High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin disease
Sigbjorn Berentsen et al.
BLOOD (2010)
Anovel approach to preventing the hemolysis of paroxysmal nocturnal hemoglobinuria: both complement-mediated cytolysis and C3 deposition are blocked by a monoclonal antibody specific for the alternative pathway of complement
Margaret A. Lindorfer et al.
BLOOD (2010)
Clinical immunology of chronic cold agglutinin disease
Elling Ulvestad et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2010)
The complement system in systemic autoimmune disease
Min Chen et al.
JOURNAL OF AUTOIMMUNITY (2010)
Long-term efficacy of the complement inhibitor eculizumab in cold agglutinin disease
Alexander Roeth et al.
BLOOD (2009)
Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab
Antonio M. Risitano et al.
BLOOD (2009)
FDA Report: Eculizumab (Soliris (R)) for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria
Andrew Dmytrijuk et al.
ONCOLOGIST (2008)
Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria
Robert A. Brodsky et al.
BLOOD (2008)
The role of complement C3 opsonization, C5a receptor, and CD14 in E. coli-induced up-regulation of granulocyte and monocyte CD11b/CD18 (CR3), phagocytosis, and oxidative burst in human
Ole-Lars Brekke et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2007)
Primary chronic cold agglutinin disease: An update on pathogenesis, clinical features and therapy
Sigbjorn Berentsen et al.
HEMATOLOGY (2007)
The role of complement in inflammatory diseases from behind the scenes into the spotlight
Maciej M. Markiewski et al.
AMERICAN JOURNAL OF PATHOLOGY (2007)
Rituximab in chronic cold agglutinin disease:: a prospective study of 20 patients
C Schöllkopf et al.
LEUKEMIA & LYMPHOMA (2006)
Cell-derived anaphylatoxins as key mediators of anti body-dependent type II autoimmunity in mice
V Kumar et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Autoantibody activity in Waldenstrom's macroglobulinemia
MJ Stone et al.
CLINICAL LYMPHOMA (2005)
Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients
S Berentsen et al.
BLOOD (2004)
Severe cold hemagglutinin disease (CHD) successfully treated with rituximab
M Engelhardt et al.
BLOOD (2002)
Acute phase haemolysis in chronic cold agglutinin disease
E Ulvestad et al.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2001)
Share Paper
